Exhibit 99.1 Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update -- 30th patient dosed in CB-010 ANTLER Phase 1 trial dose expansion; initial dose expansion data and RP2D to be disclosed in Q2 2024 -- -- 1st patient dosed in CB-012 AMpLify Phase 1 trial for patients with r/r AML -- -- $372.4 million in cash, cash equivalents, and marketable securities expected to fund the current operating plan into Q1 2026 -- BERKELEY, Calif., March 11, 2024 (GLOBE N ...

公司活动 - Caribou Biosciences, Inc.宣布参加多个投资者会议[1] 技术创新 - Caribou Biosciences, Inc.开发了CRISPR混合RNA-DNA引导技术，提高了基因组编辑的精度[3] 公司定位 - Caribou Biosciences, Inc.是一家专注于开发治疗疾病的CRISPR基因组编辑生物制药公司[4]

Cash Used in Operating Activities 32 During the nine months ended September 30, 2023, cash used in investing activities was $36.7 million, and during the nine months ended September 30, 2022, cash used in investing activities was $94.4 million. During the nine months ended September 30, 2023, and 2022, cash provided by financing activities was $154.3 million and $2.0 million, respectively. Our critical accounting policies are disclosed in our audited consolidated financial statements for the year ended Dece ...

A single dose of CB-010 resulted in profound tumor regression of metastatic CD19+ tumor xenografts and led to a significantly longer antitumor response and survival vs. conventional CD19-specific allogeneic CAR-T cells (expressing PD-1) | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-----------------------------|-------|-------|-------|-------|-------|---------------------|-------|-------| | PBS (negative control) | | | | | | 100 | | | | CD19 CAR-T (PD-1 positive) | | | | | | Percent survival 50 | ...

公司概况 - 公司是一家专注于开发基因编辑疗法的生物制药公司[57] - 公司的主要产品候选药物包括CB-010、CB-011和CB-012，分别针对不同类型的白血病和淋巴瘤[58] 财务状况 - 公司在2023年6月30日的净亏损为2950万美元，累计亏损达到2.548亿美元[59] - 截至2023年6月30日，公司现金、现金等价物和可市场化证券总额为2.925亿美元[78] - 公司预计现有资金足以支持未来12个月的运营计划[78] 研发支出 - 公司的研发费用主要包括内部人员成本和外部开发费用，用于产品候选药物和平台技术的开发[63][64] - 研发支出在2023年第二季度达到了26.5亿美元，较2022年同期增加了392.4万美元[67] - 研发支出在2023年上半年达到了52.2亿美元，较2022年同期增加了1570.9万美元[74] - 总体而言，公司在2023年第二季度和上半年的研发支出均有显著增长[67][74] 资金筹集与运营 - 公司自成立以来尚未通过产品销售产生任何收入，主要通过出售股票和IPO等方式筹集资金[77] - 公司与辉瑞达成了私募交易，向辉瑞出售了4690431股普通股，募集约2500万美元[79] - 公司的主要现金使用是用于资助运营支出和研发支出[81] - 公司预计需要额外资金来满足运营需求和资本需求，可能通过股权融资、债务融资、合作和战略联盟等方式筹集资金[83] - 截至2023年6月30日，公司经营活动产生的现金净流出为4312.4万美元[84] - 2023年上半年，公司的投资活动产生了3176.7万美元的现金[86] - 2023年上半年，公司融资活动提供的现金为1.92亿美元，较2022年同期的1.4百万美元有显著增长[87] 会计政策 - 公司的关键会计政策和重要判断和估计未发生重大变化[88] - 公司是一家新兴成长型公司，可以延迟采纳新的或修订后的会计准则，直到这些准则适用于私人公司[92]

This presentation shall not constitute an offer to sell or the solicitation of an offer to buy any securities. events versus 1 CRISPR Fewer off-target st generation Time 11 Corporate Presentation | May 2023 ©2023 Caribou Biosciences, Inc. Healthy donor leukapheresis-derived T cells ©2023 Caribou Biosciences, Inc. All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These for ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ______________________________________ FORM 10-Q ______________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40631 ______________________________________ Caribo ...

Experienced management team Corporate presentation Transformative genome-edited therapies for patients In light of the foregoing, you are urged not to rely on any forward-looking statement or third-party data in reaching any conclusion or making any investment decision about any securities of the Company. The forward-looking statements in this presentation are made only as of the date hereof. Except to the extent required by law, the Company assumes no obligation and does not intend to update any of these f ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________ For the fiscal year ended December 31, 2022 For the transition period from to Delaware 45-3728228 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes o No x Indicate by c ...

February 2023 Corporate Presentation Transformative genome-edited therapies for patients Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements speak only as of the date of this presentation and are subject to a number of known and unknown risks, assumptions, uncertainties, and other factors that may cause the actual ...